Last reviewed · How we verify

sulfalene-pyrimethamine plus amodiaquine

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

sulfalene-pyrimethamine plus amodiaquine is a Antimalarial Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Treatment of uncomplicated malaria. Also known as: Dualkin.

Sulfalene-pyrimethamine plus amodiaquine is an antimalarial combination that works by inhibiting the growth of the malaria parasite.

Sulfalene-pyrimethamine plus amodiaquine is an antimalarial combination that works by inhibiting the growth of the malaria parasite. Used for Treatment of uncomplicated malaria.

At a glance

Generic namesulfalene-pyrimethamine plus amodiaquine
Also known asDualkin
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntimalarial
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Sulfalene-pyrimethamine is a combination of sulfadoxine and pyrimethamine, which are sulfonamide and dihydrofolate reductase inhibitors, respectively. Amodiaquine is a 4-aminoquinoline antimalarial that works by interfering with the parasite's heme detoxification pathway. Together, they provide a synergistic effect against the malaria parasite.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sulfalene-pyrimethamine plus amodiaquine

What is sulfalene-pyrimethamine plus amodiaquine?

sulfalene-pyrimethamine plus amodiaquine is a Antimalarial drug developed by London School of Hygiene and Tropical Medicine, indicated for Treatment of uncomplicated malaria.

How does sulfalene-pyrimethamine plus amodiaquine work?

Sulfalene-pyrimethamine plus amodiaquine is an antimalarial combination that works by inhibiting the growth of the malaria parasite.

What is sulfalene-pyrimethamine plus amodiaquine used for?

sulfalene-pyrimethamine plus amodiaquine is indicated for Treatment of uncomplicated malaria.

Who makes sulfalene-pyrimethamine plus amodiaquine?

sulfalene-pyrimethamine plus amodiaquine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is sulfalene-pyrimethamine plus amodiaquine also known as anything else?

sulfalene-pyrimethamine plus amodiaquine is also known as Dualkin.

What drug class is sulfalene-pyrimethamine plus amodiaquine in?

sulfalene-pyrimethamine plus amodiaquine belongs to the Antimalarial class. See all Antimalarial drugs at /class/antimalarial.

What development phase is sulfalene-pyrimethamine plus amodiaquine in?

sulfalene-pyrimethamine plus amodiaquine is in Phase 3.

What are the side effects of sulfalene-pyrimethamine plus amodiaquine?

Common side effects of sulfalene-pyrimethamine plus amodiaquine include Nausea, Vomiting, Diarrhea.

Related